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Abstract
Ovarian cancer is a disease characterised by complex genomic rearrangements but the majority of the genes that are the
target of these alterations remain unidentified. Cataloguing these target genes will provide useful insights into the disease
etiology and may provide an opportunity to develop novel diagnostic and therapeutic interventions. High resolution
genome wide copy number and matching expression data from 68 primary epithelial ovarian carcinomas of various
histotypes was integrated to identify genes in regions of most frequent amplification with the strongest correlation with
expression and copy number. Regions on chromosomes 3, 7, 8, and 20 were most frequently increased in copy number
(.40% of samples). Within these regions, 703/1370 (51%) unique gene expression probesets were differentially expressed
when samples with gain were compared to samples without gain. 30% of these differentially expressed probesets also
showed a strong positive correlation (r$0.6) between expression and copy number. We also identified 21 regions of high
amplitude copy number gain, in which 32 known protein coding genes showed a strong positive correlation between
expression and copy number. Overall, our data validates previously known ovarian cancer genes, such as ERBB2, and also
identified novel potential drivers such as MYNN, PUF60 and TPX2.
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Introduction
While progress has been made in elucidating the molecular
events that underlie the development of ovarian cancer, the
identity of the majority of genes which drive the development of
this disease remain elusive. Numerous gene expression studies
have identified lists of genes with significantly altered expression,
but disappointingly there is little consensus between studies [1].
While gene expression studies are useful in identifying broad
categories of pathways altered in cancer and clinically important
subtypes [2], on their own they may not be able to distinguish the
genetically altered key driver genes. An alterative strategy used to
identify driver genes has been annotation of recurrent chromo-
somal aberrations. Early studies were hampered because the
technologies for genome-wide genomic analysis lacked the
resolution to adequately refine cancer associated loci [3]. The
problem of resolution has been overcome with the development of
ultra-high resolution aCGH and SNP arrays. Recently, our group
has used these latest-generation SNP arrays to annotate even small
regions (as small as 25 kb) of genomic alteration [4]. This data also
demonstrated that the genetic events occurring in ovarian cancers
are more numerous and complex than previously suspected. While
some potential driver genes could be rapidly identified from this
data due to their location on focal alterations, the majority of
recurrent alterations are large and encompass numerous genes.
To expedite identification of ovarian cancer growth promoting
genes we have integrated matching DNA copy number and gene
expression data from a cohort of 68 primary epithelial ovarian
cancers. We have particularly focused on genes in regions of copy
number gain, with the expectation that expression of a driver gene
within an amplicon will be more tightly correlated with gene copy
number than co-amplified genes whose expression is agnostic to
tumorigenesis. Integration of copy number and expression has
provided a list of candidate dominantly acting driver genes, which
can be used to underpin functional analysis that will be necessary to
validate their contribution to ovarian tumorigenesis. In addition, the
amplified and over expressed genes have the potential to serve as
useful therapeutic or diagnostic markers for ovarian cancer.
Results
Frequency of copy number alterations (CNA) in ovarian
cancer
Assessment of CNA in 72 epithelial ovarian tumours (Table 1,
Table S1) yielded a total of 36,534 segments comprising 20,570
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with CN gain per tumour was 208, accounting for an average of
13.6% of the genome per sample (Table S2). The median number
of regions with CN loss was 194 representing 12.2% of the
genome. These CNAs occurred across the genome but there were
some very frequent recurrent regions of CNA among the 72
tumours (Figure 1) including gains located on 1q, 3q, 6, 7q, 8q, 19,
and 20 and losses on chromosomes 4, 6, 8, 13, 16, 17, 18, 22q and
X. Within epithelial ovarian cancer histotypes we noted that
mucinous and to a lesser extent clear cell cases appeared to have
fewer CNAs and a smaller proportion of the genome was involved
compared to the other subtypes (Figure S1). However, the
numbers of samples in the minor subtypes were small, making it
difficult to draw statistically valid conclusions about subtype
specific changes. Most of the samples were of the serous or related
high grade endometrioid subtype and many of the regions of gain
and loss are primarily driven by these subtypes.
Integration of mRNA expression in regions of frequent
copy number gain
A common mechanism of activation of gene function in cancer
development is through over expression as a consequence of gene
amplification. While many genes may be located within a
particular amplicon, the targeted gene(s) would be expected to
consistently show elevated expression compared with adjacent
bystander genes [5]. We have previously conducted an integrated
expression analysis of candidate tumour suppressor genes within
regions of loss of heterozygosity on an overlapping tumour cohort
[6], thus for this study we chose to focus on the identification of
candidate genes located within amplicons. An arbitrary frequency
threshold of at least 40% was chosen as a filter for selecting key
regions, resulting in the demarcation of multiple chromosomal
regions on 3q, 7q, 8q and 20q (Figure 2). Each segment of frequent
CN gain was labelled by the cytoband it belonged to; following
which regions with the same cytoband tag were collapsed into one
larger region (Figure S2-A). Those regions overlapping with
germline copy number polymorphism (CNPs, Table S3) were
excluded as described in Figure S2-B. The final 106 amplicons
ranged in size from 11 kb to 7 Mb (Table S4) and 90 of these
regions in total contained 1370 gene expression probesets on the
Affymetrix Gene 1.0ST array corresponding to 938 known protein
coding genes. The other 16 amplicons were not represented by
probesets on the Gene 1.0ST arrays.
Expression analyses were carried out for probesets within each
of the 90 regions (Tables 2, 3, 4, Table S5). For each region groups
of samples that showed copy number gain (3 or more copies) were
tested for differential expression against groups of samples that
showed normal copy number (,2 copies). Across all regions, there
were 703 (51%) differentially expressed probesets corresponding to
629 genes with unique identifiers such as an HGNC gene symbol
or Ensembl ID (Table S5). Only one gene, hCG_16001, showed a
negative log fold change (20.34, Figure S3). On average (in
regions with at least 5 probesets), 50% of the probesets were found
to be differentially expressed suggesting a generalised increase in
expression of genes within CN gains. Interestingly, we observed
that MYC, an oncogene characterised by copy number gain in a
wide variety of tumour types, was not significantly differentially
expressed between amplified and unamplified groups of samples.
One possibility is that MYC is expressed at a high level across all
Table 1. Summary of samples analysed by SNP and expression array.
Grade FIGO Stage
Subtype 1 2 3 NK 1 2 3 NK
Clear Cell (9) 2 2 3 2 3 1 2 3
Endometrioid (14) 2 4 8 0 8 2 4 0
Mucinous (7) 5 2 0 0 4 0 2 1
Serous (37) 3 11 20 3 3 10 17 7
Undifferentiated (1) 1 0 0 0 0 1 0 0
NK, grade or stage not known. Information for 68 tumours that had both high quality expression and copy number data is listed here. Four more samples that were
used in the copy number analyses alone are detailed in Table S1.
doi:10.1371/journal.pone.0009983.t001
Figure 1. Overview of genomic aberrations in the ovarian cancer dataset (N=72). Frequency of occurrence of genomic gains (yellow) and
losses (blue) across the genome, depicted in chromosome order from 1p to Xq.
doi:10.1371/journal.pone.0009983.g001
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different between groups of tumours that show a gain and those
that do not. To test this possibility we compared expression of
MYC in amplified ovarian cancer samples to expression in normal
fallopian tube epithelium. We did not find any increase in MYC
expression when comparing tumours to these samples (p=0.41,
Welch corrected unpaired t-test, Figure S4).
To further refine this list of 703 copy number driven,
differentially expressed probesets, we reasoned that those genes
showing the strongest correlation of copy number and expression
may be the most likely genes targeted by the CN gain. Thus, we
calculated the correlation co-efficient for all differentially expressed
genes with copy number probeset coverage in the candidate
amplicons (Table S5). Of the 692 probesets tested (11 did not
contain copy number probes), 219 (corresponding to 206 protein-
coding genes) showed a strong positive correlation (r$0.6) between
expression and copy number.
Genes targeted by high CN amplification
Our main approach to identify cancer-related genes was to filter
for the most frequent aberrations but we noted that well
characterised cancer driver genes, such as CCNE1 and ERBB2
[7], were not identified since they were amplified in less than 40%
of tumours. Rather than using a lower cut-off which would risk
including many regions altered due to generalised genomic
instability (for example ,67% of the genome would be considered
as candidate regions if a cut-off of .10% was used), we instead
filtered for genes showing a high amplitude CN gain. Here, we
looked at all segments that had a copy number greater than or
equal to 5 and were present in at least 5 samples, which identified
21 regions over 27.2 Mb (Table 5). These regions corresponded to
181 gene expression probesets on our Affymetrix Gene 1.0ST
arrays, of which 39 (22%) had a strong positive correlation
between CN and gene expression (r.0.6). These probesets
corresponded to 32 known protein coding genes including well
known cancer driver genes such as ERBB2 (Table S6).
Prioritising candidate driver genes
In order to prioritise the most promising candidates from the
previous analyses, we built a gene list using the following criteria.
Firstly, we selected those known genes with a high frequency of
gain (.40%), that were differentially expressed (n=629). From
this list we selected the genes most strongly over expressed by the
level of log fold change (.0.7) between samples with CN gain and
samples that were neutral at the locus (n=59). As a different
measure of how gene expression was affected by copy number, we
also selected genes that showed a strong correlation (.0.7) of copy
number and expression (n=58). The union of these criteria
produced a list of 110 genes. From this list, we identified genes on
each chromosome that were the most frequently affected by copy
Figure 2. Detailed view of chromosomes showing frequent gains. Frequent gains occur on chromosomes 3, 7, 8 and 20, with each point
indicating the frequency of gain of a CN segment. The red line in all panels indicates the 40% frequency threshold.
doi:10.1371/journal.pone.0009983.g002
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$60%, for chr3, $50% and for chr20 $42%. This list comprised
37 genes (Table 6).
Secondly, we also wished to include genes that were highly
amplified. From our list of highly amplified genes in at least 5
samples we selected those that had a strong positive correlation
between copy number and expression (r.0.6, n=32). Some of the
genes that were highly amplified were also differentially expressed
based on the expression analysis of frequently gained regions, so
we also included genes with a log fold change greater than 0.6
(n=17). Taking genes satisfying one or the other of these criteria,
we added 41 genes to our high priority list (Table 6).
When we combined these two gene lists, the first based on ‘‘high
frequency’’ and the second on ‘‘high amplitude’’ but both with
increased expression, the final number of unique genes was 70
(Table 6).
Discussion
Gene expression analysis has been widely used to identify key
pathways and clinically important subgroups in ovarian cancer but
identification of specific driver genes using this methodology alone
has been hampered by the fact that expression is rather plastic and
there has been little consensus in the genes identified between such
studies [1,8]. One reason for this lack of consistency is that most
studies have analysed RNA from whole tumour samples without
verification of the percentage cancer epithelium and/or have used
diverse control tissues such as whole ground ovary [9]. In contrast
to gene expression, genomic alterations may be a more stable and
reliable predictor of the location of driver genes. Ovarian cancer
has long been suspected to be cytogenetically complex [10] and
recent advances in genomics technology has confirmed the
profound genomic aberrations that characterise most ovarian
cancers [4,11,12,13]. Despite this complexity, published copy
number profiles of ovarian cancers are highly comparable at a
global level [3] and many studies have identified very similar
regions of frequent copy number alteration. However, progress at
identifying key driver genes has been slow, with different studies
often identifying different candidates in the same genomic region.
For example, the chromosome 20 amplicon driver has variously
been suggested to be ADRM1 [14], EYA2 [15], AURKA and
ZNF217 [16], among several others. Early studies integrating
expression and copy number data have either used cancer cell
lines to identify over expressed genes [17,18] and/or microarray
Table 2. Genes with increased expression on chromosomes 3 and 7.










3 Most significant DE Genes
4
3_1 3 157.223 157.972 30 37 3 (60) SSR3; TIPARP; KCNAB1
3_2 3 158.260 159.895 31 36 8 (62) MLF1; GFM1; RSRC1; CCNL1; PTX3; VEPH1; LXN; SHOX2
3_3 3 159.895 159.959 30 37 2 (100) RARRES1
3_4 3 159.959 161.006 32 35 2 (50) MFSD1; SCHIP1
3_5 3 161.006 161.392 30 37 3 (75) SCHIP1;IL12A
3_7 3 161.392 168.660 33 35 8 (24) KPNA4; SMC4; B3GALNT1; NMD3; TRIM59; hCG_16001; IFT80
3_8 3 168.697 168.916 37 31 1 (50) PDCD10
3_9 3 168.916 169.209 38 30 2 (100) PDCD10; SERPINI1
3_10 3 169.209 172.478 41 27 12 (40) MYNN; PHC3; SKIL; MDS1; ARPM1;TLOC1; PRKCI; EVI1; EIF5A2;
SLC7A14
3_12 3 172.586 177.095 39 29 2 (8) ECT2; AADACL1
3_14 3 177.366 180.518 39 29 4 (27) TBL1XR1; PIK3CA
3_15 3 180.518 180.608 35 33 3 (100) ZNF639; MFN1;GNB4
3_17 3 180.608 181.970 36 32 6 (43) ACTL6A; MRPL47; NDUFB5; GNB4; LOC442098; TTC14
3_18 3 181.971 184.153 34 34 4 (57) FXR1; DNAJC19; DCUN1D1; ATP11B
3_19 3 184.153 184.291 35 33 2 (100) DCUN1D1;MCCC1
3_20 3 184.291 185.996 34 34 18 (50) ABCF3*; PSMD2; AP2M1; EIF4G1; PARL; ALG3; KLHL24; POLR2H;
EIF2B5*; DVL3*; YEATS2; MAGEF1; MCCC1; LAMP3; ABCC5
3_22 3 186.007 187.399 36 32 5 (31) SENP2; TMEM41A*; SFRS10; VPS8;EHHADH
3_24 3 187.519 189.379 35 33 10 (42) RFC4*; RPL39L*; DNAJB11; EIF4A2; TBCCD1; SNORA4; ST6GAL1;
BCL6; RTP4
3_25 3 189.379 189.430 38 30 2 (100) LPP; FLJ42393
3_27 3 193.766 193.936 35 33 1 (50) FGF12
3_28 3 193.936 199.337 31 37 36 (46) WDR53*; FBXO45*; NCBP2; LSG1; PIGX; RNF168; SENP5; OPA1;
FYTTD1; CENTB2; UBXD7; PCYT1A; ATP13A3; KIAA0226*; DLG1
7_1 7 141.416 141.431 34 33 1 (100) MGAM
1. Start and end position of regions in Mbp based on hg18 (March 2006 release).
2. Number of samples with copy number gains (G) and normal copy number (N) used in the expression analysis. Samples with copy number loss were not included.
3. Number of differentially expressed (DE) probesets by expression microarray. Regions with no DE named genes are not shown here but are listed in TableS 4 .
4. Only coding genes with a symbol (from Affymetrix array annotation) are listed here and hence can differ from the number quoted in brackets. For a full list see Table
S5. Genes for each region are listed in decreasing order of significance, with only the top 15 most significant listed.
*indicates genes with a correlation coefficient of .0.7.
doi:10.1371/journal.pone.0009983.t002
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To date few studies have exploited a truly genome-wide integrated
copy number and expression analysis on matched samples for the
unbiased identification of candidate genes [21,22,23] and there
has only been one previous study of a smaller cohort of ovarian
tumours [12]. In this study we have therefore attempted to
circumvent some of the issues of examining expression or copy
number in isolation by integrating two data sets obtained from
microdissected tumour epithelial cells.
As a first pass of the data we focussed on gains occurring in a
very high proportion of cases which included regions of
chromosomes 3, 7, 8 and 20. Identification of differentially
expressed genes reduced our list of candidate cancer genes in these
regions by approximately half (range 6–89% for regions with at
least 5 probesets). We have validated several of the genes identified
in Haverty et al., for example, on 3q26.2 we confirmed increased
expression in 7/8 of their genes. However, we have also identified
a number of additional amplified and over expressed genes
(Tables 2, 3, 4), most likely due to differences in our method and
larger sample size. The proportion of differentially expressed genes
in our study is consistent with previous studies of other cancer
types [24] supporting the concept that copy number can have a
strong influence on gene expression. Consequently, for many
regions we were not able to identify one particular driver gene. It is
possible that there may truly be many driver genes within each
amplicon and although each may individually contribute little to
cancer progression, coordinate over expression of these genes in
amplified regions may have an additive or synergistic oncogenic
Table 3. Genes with increased expression on chromosome 8.










3 Most significant DE Genes
4
8_1 8 53.390 55.545 29 39 11 (73) ATP6V1H*; MRPL15; TCEA1; LYPLA1; RB1CC1; RGS20; NPBWR1;
SOX17; UNQ9433
8_5 8 60.387 61.696 35 32 6 (60) XKR4; TGS1*; TMEM68*; RP1
8_7 8 61.696 61.817 35 32 2 (100) RAB2A; CHD7
8_13 8 62.549 65.928 33 33 3 (21) RLBP1L1*; YTHDF3
8_15 8 66.237 68.051 33 33 14 (67) ARMC1; VCPIP1; C8orf44; RRS1; SGK3; C8orf45; MYBL1; ADHFE1;
MTFR1; C8orf46
8_16 8 68.051 68.292 29 36 6 (100) COPS5; ARFGEF1; CSPP1
8_19 8 70.815 73.993 32 35 9 (41) KCNB2; NCOA2; TRPA1; TRAM1; MSC
8_21 8 74.016 78.270 34 33 8 (32) TMEM70; STAU2; PXMP3; TERF1; UBE2W; TCEB1
8_25 8 80.419 84.683 36 31 10 (40) CHMP4C; ZNF704; ZBTB10; SNX16; ZFAND1
8_27 8 85.122 87.055 34 33 16 (67) C8orf59; REXO1L2P; REXO1L1; E2F5
8_30 8 87.250 89.422 34 33 5 (50) WWP1; FAM82B; CPNE3; WDR21C; CNGB3
8_31 8 89.426 93.278 37 29 7 (35) OTUD6B; NBN; TMEM55A; SLC26A7; RUNX1T1; TMEM64
8_33 8 93.587 98.637 38 28 17 (53) UQCRB; TP53INP1; C8orf38; MTERFD1; PLEKHF2; PTDSS1;
KIAA1429; RBM35A; INTS8; TSPYL5
8_34 8 98.637 99.159 35 32 7 (88) MTDH; LAPTM4B; MATN2; RPL30
8_36 8 99.159 100.102 37 30 9 (82) POP1*; NPAL2; STK3; VPS13B; HRSP12; OSR2; KCNS2
8_37 8 100.112 101.579 37 30 6 (55) COX6C; RNF19A; POLR2K; VPS13B; FBXO43
8_38 8 101.579 101.675 36 31 2 (100) ANKRD46; MGC39715
8_39 8 101.675 105.906 39 28 25 (50) YWHAZ; WDSOF1; FLJ45248; ATP6V1C1; ZNF706; UBR5; FZD6;
PABPC1; AZIN1; MGC39715
8_43 8 107.681 110.578 39 28 4 (31) ENY2; TTC35; NUDCD1; OXR1
8_45 8 110.578 110.700 38 29 2 (67) EBAG9; GOLSYN
8_52 8 113.663 117.487 40 27 1 (25) TRPS1
8_54 8 117.713 119.186 42 25 8 (89) RAD21; C8orf53; MED30; EXT1; EIF3H; SLC30A8
8_56 8 119.298 121.983 44 23 6 (35) MTBP;DCC1; TAF2; MRPL13; SAMD12; MAL2
8_59 8 122.661 122.935 40 27 1 (100) HAS2
8_60 8 122.935 127.209 44 23 24 (60) C8orf76*; RNF139; DERL1; ATAD2; TRMT12; NDUFB9; ZNF572;
TMEM65; C8orf32; SQLE
8_63 8 127.320 129.639 46 21 2 (25) FAM84B
8_66 8 129.735 131.499 47 20 4 (50) FAM49B; MLZE; DDEF1
8_69 8 131.596 135.232 44 23 9 (45) TG; OC90; KCNQ3; NDRG1; KIAA0143; PHF20L1; WISP1; SLA
8_72 8 135.435 136.466 43 24 2 (67) ZFAT1*
8_76 8 137.616 139.944 42 25 2 (100) COL22A1; FAM135B
8_78 8 140.056 146.269 43 24 89 (74) ZC3H3*; PUF60; GPR172A; CYHR1; SCRIB; HSF1 ; ZNF7*; MAF1;
SHARPIN; BOP1
1.-4. Please see legend to Table 2, except that only the top 10 genes are listed and genes present in more than one region are only shown in one of these.
doi:10.1371/journal.pone.0009983.t003
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may be passengers whose over expression endows no selective
advantage or disadvantage to the tumour. Discriminating between
passengers and drivers within a genomic region may therefore only
be achieved through large-scale functional analyses and combina-
torial approaches examining many genes in concert.
Despite the relatively large number of amplified and differen-
tially expressed genes identified in this study, we still hypothesise
that those genes showing the strongest over expression, and also
those genes with the highest amplitude copy number gains, may be
more likely to be drivers of tumorigenesis than weakly over
expressed genes. Hence, we prioritised our gene list using stringent
expression criteria. For example, one of the genes most frequently
targeted by copy number that is strongly over expressed is PUF60
(poly-U binding splicing factor 60 kDa). This gene encodes for a pre-
mRNA splicing factor thought to be involved in the recognition of
39 splice sites [25]. It may also inhibit transcription by interacting
with the TFIIH helicase, the key factor mutated in the cancer-
prone syndrome xeroderma pigmentosum, and this interaction is
implicated in the correct regulation of MYC transcription [26,27].
Myoneurin or MYNN is a gene that is located in a region of
frequent (60%) copy number gain on 3q26.2. It is differentially
expressed (adjusted p=1.51E-05) between amplified and unam-
plified groups, and shows the strongest correlation between copy
number and expression (r=0.74, Figure 3) amongst all genes in
this region. This gene was identified as a member of the Broad
complex, Tramtrack, Bric a’ brac (BTB) or poxvirus and zinc
finger (POZ)-ZF i.e BTB/POZ-ZF family of transcription factors
[28]. First discovered in Drosophila, this family consists of about 60
human proteins including several cancer related proteins such as
leukaemia related factor (LRF/ZBTB7) and B-cell lymphoma 6
(BCL6). While the role of MYNN in cancer is yet to be
characterised, other members of this family are similarly
overexpressed in tumors [29].
As well as identifying high frequency, differentially expressed
genes, including known cancer genes such as PIK3CA and AURKA,
we also used high amplitude regions to locate additional known
(e.g. ERBB2 and CCNE1) and potential oncogenes. For example,
on chromosome 20, the high-amplitude approach identified a
small minimal region that was not evident from the low-amplitude
analysis. This 421 kb interval at 20q11.21 encompasses 10 genes,
of which TPX2 showed the strongest correlation with copy number
(r=0.53). This gene was also differentially expressed between
samples with any TPX2 gain and those with normal TPX2 copy
number, and had the strongest fold change of any gene on
chromosome 20 (log2 fold change of 1.03). The protein encoded
by this gene functions as an activator of Aurora-A with a role in
spindle assembly [30]. Interestingly for ovarian cancer, it has been
shown to interact with the BRCA1/BARD1 complex (15).
Recently, it has been identified as a potential oncogene in
pancreatic cancer [31].
In summary, our study shows that combining the high frequency
and high amplitude analyses and targeting the most strongly over
expressed genes reduced the candidate list to just70 genes out of the
Table 4. Genes with increased expression on chromosome 20.










3 Most significant DE Genes
4
20_1 20 29.299 31.465 34 34 34 (62) POFUT1; PDRG1; PLAGL2 ;ASXL1; TM9SF4; TPX2; CDK5RAP1;
MAPRE1; COMMD7; KIF3B; C20orf112; RP11-49G10.8; DEFB118;
DUSP15; DNMT3B
20_2 20 31.466 31.648 29 39 2 (100) CBFA2T2; SNTA1
20_4 20 31.649 33.694 31 37 34 (74) PIGU; DYNLRB1; GGTL3; RBM12; RALY; NCOA6*;CEP250*;
APBA2BP; TRPC4AP; EIF6; EDEM2; GSS; UQCC; PXMP4; EIF2S2
20_5 20 33.696 33.760 36 32 5 (100) RBM12; NFS1; RBM39; C20orf52
20_6 20 33.958 37.049 29 39 38 (64) CTNNBL1*; LOC388796; KIAA0406P; DHX35*; C20orf77; ACTR5;
MANBAL; FAM83D; DSN1; RBL1; C20orf198; RPN2; SCAND1;
C20orf117; C20orf24
20_7 20 37.107 41.095 29 37 11 (65) PLCG1; CHD6; LPIN3; TOP1; PTPRT; LOC149692; ZHX3; EMILIN3;
MAFB
20_8 20 41.095 41.113 30 36 1 (100) PTPRT
20_9 20 41.124 41.226 28 38 2 (100) PTPRT
20_10 20 42.962 45.772 30 37 45 (62) PIGT; UBE2C; ZSWIM1; TOMM34; DNTTIP1*; NCOA5; SLC35C2;
ACOT8; NEURL2; KCNS1; C20orf67; SNX21; ELMO2; ZMYND8;
TP53RK;
20_12 20 45.850 49.180 29 38 23 (61) TMEM189*; MOCS3*; DPM1; STAU1; DDX27; CSE1L; ARFGEF2;
ADNP; SPATA2*; PTPN1; SLC9A8*; C20orf199; PARD6B; ZNF313;
KCNG1
20_14 20 49.222 54.379 30 37 10 (42) ZFP64*; AURKA; PFDN4; ATP9A; MC3R; TSHZ2; SUMO1P1
20_15 20 54.379 54.417 27 41 2 (100) CSTF1; AURKA
20_16 20 54.417 55.828 31 36 8 (32) C20orf43; RAE1; BMP7; RBM38; GCNT7
20_18 20 55.991 57.887 33 34 12 (57) VAPB; TUBB1; RAB22A; TH1L; SLMO2; STX16; ATP5E; GNAS;
SYCP2; PPP4R1L; NPEPL1
20_20 20 57.901 62.427 33 34 38 (45) LSM14B*; YTHDF1; SS18L1; DIDO1; GTPBP5; PSMA7; TAF4;
C20orf11; C20orf20; TCFL5; C20orf177; MYT1; PCMTD2; DNAJC5;
TPD52L2;
1.-4. Please see legend to Table 2.
doi:10.1371/journal.pone.0009983.t004
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identified many promising candidate genes not previously noted in
ovarian cancer, particularly genes such as MYNN, TPX2 and
PUF60. It should be noted, however, that our method of analysis is
one of many that can be employed in the identification of novel
cancer genes, and is unlikely to have identified all possible
candidates. The example of MYC, not strongly expressed in our
data but previously shown to have a functional effect in ovarian
cancer cell lines [32], clearly indicates that our approach should be
considered complementary to others such as functional screens and
deep sequencing of primary cancer samples. Nevertheless our data
provides an important platform from which to rationally pursue the
validation of these potential dominant drivers of ovarian tumori-
genesis. In addition, this list may include genes that are valid
candidates for diagnostic or therapeutic purposes.
Materials and Methods
Ethics Statement
All samples were collected with the donor’s written informed
consent. This study was approved by the Peter MacCallum Cancer
Centre Human Research Ethics Committee (Protocol number 01/38).
Sample collection
Tumour biopsies were obtained from 72 patients who were
undergoing surgery for primary ovarian cancers (a) at hospitals in
the Wessex region of Southeast England, UK and (b) in hospitals
in Victoria, Australia (accessed through the Peter MacCallum
Cancer Centre Tissue Bank). Blood was collected from the same
patients for matching lymphocytes. Fallopian tube samples were
collected through the tissue bank from BRCA1 or BRCA2 mutation
carriers undergoing prophylactic bilateral salpingo-oophorectomy
in hospitals around Melbourne. The accrual and use of patient
samples related to this project were approved by the relevant
institutional ethics committees. Clinical and histopathological
information about the samples are provided in Table 1 and Table
S1.
DNA and RNA extraction
Fresh-frozen tissue was embedded in Optimal Cutting Tem-
perature Compound (OCT, Sakura Finetek, Torrance, CA) and
cut into 10 mm sections. Tumour DNA and tumour and fallopian
tube RNA were extracted from identical regions after needle
micro-dissection of .80% tumour epithelial cells. Sections for
RNA were stained using Cresyl violet and RNA was extracted
using Ambion mirVana total RNA extraction protocol (Applied
Biosystems/Ambion, Austin, TX). Tissue sections used for DNA
extraction were stained with haematoxylin and eosin and DNA
was extracted using the Qiagen Blood and Tissue Kit (Qiagen,
Valencia, CA, USA). DNA from matching normal lymphocytes
for samples from the Peter MacCallum Cancer Centre Tissue
Bank were extracted using the same kit. DNA from matching
Table 5. Highly amplified genes.
Chr Start (Mb) End (Mb) Length (bp) No. samples Genes
1
3 170.040 170.248 208141 6 None
3 178.305 178.589 283690 5 TBL1XR1
3 180.121 180.410 288435 5 PIK3CA; ZMAT3
8 55.208 55.528 319922 5 MRPL15*
8 62.495 63.491 995369 6 RLBP1L1*;NKAIN3;ASPH
8 102.003 102.062 58823 5 YWHAZ
8 123.144 123.746 601615 6 None
8 123.856 124.369 513120 6 DERL1; ZHX2; WDR67*; ZHX1*; C8orf76*; FAM83A
8 124.369 125.825 1455953 6 ATAD2; C8orf32*; FBXO32; ANXA13; KLHL38; FAM91A1; FER1L6; MTSS1;
NDUFB9; RNF139; TATDN1; TMEM65; TRMT12*
8 125.828 127.764 1936500 7 KIAA0196; NSMCE2; SQLE; ZNF572*; TRIB1; FAM84B*
8 127.764 128.973 1208920 7 MYC; POU5F1P1
8 128.973 130.166 1193146 8 PVT1
{, TMEM75*
8 130.166 138.988 8821634 7 ADCY8; DDEF1; EFR3A; FAM49B; KCNQ3; MLZE; OC90; LRRC6; NDRG1;
PHF20L1; SLA; TG*; TMEM71; WISP1; ST3GAL1; ZFAT*; KHDRBS3; CCDC26
8 138.988 144.000 5382420 7 FAM135B; COL22A1; KCNK9; NIBP*; CHRAC1*; EIF2C2; PTK2; DENND3*;
SLC45A4; FLJ43860; GPR20; PTP4A3; ARC; BAI1; C8orf55; CYP11B1;
CYP11B2; GML; JRK; LY6D; LY6K; LYNX1; LYPD2; PSCA; SLURP1; TSNARE1
17 35.104 35.105 529 5 ERBB2*
19 34.125 34.639 513414 5 UQCRFS1*
19 34.639 35.610 971542 6 C19orf12*; PLEKHF1; POP4*; CCNE1; C19orf2; ZNF536*
19 35.968 36.703 734619 6 TSHZ3*
19 37.459 38.011 552023 5 ANKRD27*; PDCD5*; RGS9BP; ECAT8; DPY19L3*; ZNF507*
19 38.372 39.140 767924 5 CEBPA; LRP3; SLC7A10; CHST8; KCTD15; CEBPG*; PEPD*; FLJ12355
20 29.427 29.849 421241 5 BCL2L1; COX4I2; DEFB119; DEFB121; DEFB123; DEFB124; HM13; ID1; REM1; TPX2
1. Derived from Refseq annotation (September 2009). Genes in italics are known oncogenes (based on Cancer Gene Census [38]), *Genes that show a strong (r.0.6)
positive correlation of copy number with expression,
{Not on expression microarray. Note that some regions encompass multiple smaller amplicons, only genes within
regions (+/210 kb) defined by .5 samples are shown.
doi:10.1371/journal.pone.0009983.t005
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extracted as described previously [33].
Microarray data generation and quality control
500 ng of DNA from each tumour sample was analysed using
the Affymetrix Genome-wide Human SNP Array 6.0 (SNP6.0)
following the manufacturer’s instructions (Affymetrix, Santa Clara,
CA). Where available (57 cases) DNA from matching peripheral
blood lymphocytes was analysed on the same platform and in the
same batch. For mRNA expression, 300 ng of total RNA from the
same tumour samples were analysed using the Affymetrix Human
Gene1.0 ST Array. Analysis of array performance for SNP6.0
arrays was performed using genotyping call rates (.90% call rate
required) and also visual inspection of copy number traces to
remove noisy samples. 72 samples passed quality control measures
and were used in the copy number analysis. For expression arrays,
the profiles of hybridisation controls, spike-in controls and
positive-versus-negative area under the curve (AUC) were assessed
using Affymetrix Expression Console. Additionally, the quality of
the arrays was assessed based on Relative Log-Likelihood (RLE)
Table 6. Candidate oncogenes and current literature.
Gene Chr Start End Total gain (%) Comments Other genes in region
PDCD10 3 168.884 168.935 43 Angiogenesis disorder [39], ERK pathway [40]
PRKCI 3 171.423 171.506 51 Oncogene in ovarian and other cancers [41,42] SKIL, PHC3, MYNN
ECT2 3 173.955 174.022 50 Cytokinesis [43]. Transforming protein [44]. Interacts
with PRKCI [45]
TBL1XR1* 3 178.221 178.398 50 Oncogene in breast cancer [46], transcriptional
repressor [47]
PIK3CA* 3 180.349 180.435 50 Known oncogene MRPL47, NDUFB5
SENP2 3 186.787 186.832 51 SUMO1 deconjugating peptidase. Possible role in
degradation of beta-catenin [48].
TMEM41A
MRPL15* 8 55.210 55.224 42 Mitochondrial ribosomal protein [49]
RLBP1L1* 8 62.363 62.577 46 Clavesin 1 (CLVS1), regulates endosome morphology [50],
upregulated in liver cancer [51]
YWHAZ* 8 102.000 102.035 53 14-3-3 isoform zeta, oncogenic functions in inhibiting
apoptosis and adhesion [52]
DERL1* 8 124.095 124.124 60 Endoplasmic reticulum protein [53] with role in stress
response. Elevated expression in cancer [54,55]
WDR67*, C8orf76*
ATAD2* 8 124.401 124.478 60 ATPase. E2F target, binds MYC, expression correlates
with poor outcome in breast cancer [56]. Interacts with
ER and AR and is required for target gene expression [57]
WDYHV1/C8ORF32*,
FBXO32*, FAM91A1*




FAM84B* 8 127.634 127.640 61 –
FAM49B* 8 130.923 131.021 61 –
NDRG1* 8 134.319 134.379 60 Diverse role in stress response including hypoxia [59].
Fusions with ERG in prostate cancer [60].
ZFAT* 8 135.559 135.794 60 Zinc finger and AT hook protein, anti-apoptotic role [61]








PUF60 8 144.971 144.984 60 mRNA splicing factor [25] CYC1, ZNF623, ZNF7,
CYHR1
ERBB2* 17 35.098 35.138 Known oncogene in breast cancer
TPX2* 20 29.791 29.853 42 Activator of Aurora-A and involved in spindle assembly [30].
Interacts with BRCA1/BARD1 [64]
UBE2C 20 43.875 43.879 42 Ubiquitin-conjugating enzyme E2C, degradation of mitotic
cyclins and cell cycle progression [65]
PIGT
ZFP64 20 50.134 50.242 43 Zinc finger protein, Notch signalling [66]
AURKA 20 54.378 54.401 43 Aurora kinase, cell cycle regulation, chromosome
segregation, microtubule/spindle function [67]
CSTF1, RAE1, C20orf43
SS18L1 20 60.152 60.191 46 Synovial sarcoma translocation fusion gene [68]);
calcium-responsive transactivator [67]
GTPBP5, LSM14B, TAF4
Genes were selected as follows: Gain in .40% and differentially expressed, with fold change expression in gain vs. neutral of .0.7 or correlation coefficient (r) of .0.7.
Of these genes (n=121), the most frequently gained in each chromosome were selected: Chr 3 n$50, Chr8 n$60, Chr 20 n$42. 2. High level amplification in at least 5
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generated using the ‘‘affyPLM’’ package in the R open-source
software. Expression arrays that were flagged as dubious by 2 out
of 3 measures (AUC, RLE, NUSE) were excluded from expression
analyses. 68 tumour samples (57 with normal DNA) passed for
both expression and copy number and were retained in the
integrated expression analyses. The final sample set in the
integrated analysis included the four most commonly seen
histological subtypes of ovarian cancer – serous (n=37),
endometrioid (n=14), mucinous (n=7) and clear cell (n=9).
One sample in the study was of unknown histotype (Table 1). Both
gene expression and copy number data are MIAME compliant
and have been submitted to the National Centre for Biotechnology
Information’s (NCBI) Gene Expression Omnibus (GEO) website,
series accession number GSE19539.
Copy number analysis
Copy number generation and analyses were performed using
Partek
H Genomics Suite
TM version 6.03 (Partek Inc., St. Louis,
Missouri) and Bioconductor packages in the R-open source
software framework [34,35]. SNP 6.0 CEL files were imported
into Partek using default settings for background correction and
summarisation. Human Genome Build 36.1 (hg18, March 2006)
was used for base pair locations. Probeset copy number ratios were
calculated by comparing each tumour with its matching normal
when available (n=57). For samples that did not have matching
normal data (n=15), a pooled normal baseline from all the other
normal samples was used. Circular binary segmentation [36] was
performed using the R-based package ‘‘DNAcopy’’ to segment the
data into distinct regions of change using default package settings.
This analysis produced a list of regions per sample that was then
filtered for those regions that showed gain (copy number ratio
.2.5) or loss (copy number ratio ,1.5) across $40% (n$29) of all
samples. These regions were collapsed into cytobands for easier
data manipulation (Figure S2 for more detail). It is important to
note that since these regions have undergone filtering steps defined
above, they do not include the entire cytoband by which they are
represented and hence the high resolution of the data is not
compromised.
To identify potential germline copy number polymorphisms
(CNP) that could interfere with accurate identification of somatic
changes, copy number data for 57 normal samples was generated
relative to a pooled baseline of all normal samples. Regions
showing gain or loss in .5% of all samples were called as CNPs
(Table S3). Regions of interest from the tumour data were scanned
for these CNPs and matches were removed from downstream
analyses (Figure S2-B). CNP-removed, cytoband-collapsed regions
were queried against the entire copy-number dataset to generate
accurate, region-wise values of copy number.
Copy number was extracted on a gene-by-gene basis to perform
Pearson correlation analysis with expression. Since some genes
were so small that there were no copy number probesets mapping
to them, an additional 10 kb was added to all gene start and stop
positions before extracting their copy number.
Expression microarray analysis
For each candidate region, samples were divided into two
groups, G – consisting of all samples that showed gain (.3 copies)
on the SNP6.0 platform; and N – consisting of all samples that
showed normal copy number (1.5–2.5 copies). A test for
differential expression was performed between these two groups
using the ‘‘limma’’ package available on the R-open source
software platform [34]. Histological subtype was included as a
factor in the analysis. Genes were considered to be significantly
differentially expressed with a p-value of ,0.05 after multiple
testing correction [37]. A Pearson’s correlation analysis between
copy number and expression was also performed. Separate
analyses were performed on a gene-by-gene basis for all genes
within (a) most frequently amplified regions (CN$3; Freq$40%)
and (b) most highly amplified regions (CN$5; Freq$7%).
Supporting Information
Table S1 Sample details. Clinicopathological features and assay
information for each sample. 57 out of 72 tumours had matching
lymphocytic DNA available for copy number microarray analysis.
Found at: doi:10.1371/journal.pone.0009983.s001 (0.06 MB
PDF)
Table S2 Proportion of genome-wide gain and loss by sample.
In all of these samples, the aberrant genome adds up to 95.4% on
average. The missing 4.6% can be attributed to regions on
chromosome Y, Mitochondrial DNA and repetitive sequences
around centromeric regions that are either removed from the
segmentation analysis or not covered by the Affymetrix SNP6.0
array.
Found at: doi:10.1371/journal.pone.0009983.s002 (0.06 MB
PDF)
Table S3 Germline copy number polymorphisms on Chr 3, 7, 8,
20. The regions/segments of copy number gain that contained one
or more of these CNPs were removed or altered as displayed in
Figure S1-B. The type of CNP is also displayed in the far right
column.
Found at: doi:10.1371/journal.pone.0009983.s003 (0.05 MB
PDF)
Table S4 Regions of gain present in .40% of samples. This
table contains genomic information for the 90 regions included in
the expression analyses, i.e., all those regions that mapped to 1 or
more probesets on the Human GeneST1.0 microarrays. On this
microarray platform, most probesets map uniquely to a protein-
coding gene. The region IDs correspond to those in Tables 2, 3, 4
and S5.
Found at: doi:10.1371/journal.pone.0009983.s004 (0.13 MB
PDF)
Table S5 All differentially expressed probesets in frequent
regions of gain. Every probeset tested for differential expression
is listed and tagged by the region it belongs to. These region IDs
are consistent across all tables in the paper and are derived as
shown in Figure S1-A. Column 5 displays the Pearson’s
Figure 3. Correlation between copy number and expression for a frequently gained region on cytoband 3q26.2. A. Frequency of copy
number gain on chromosome 3 from p-ter at left to q-ter at right as indicated by the ideogram. B. Genes on Chr3: 169.209–172.478 Mbp, a region
gained in 60% (41/68) of all samples, including genes previously associated with ovarian cancer (PRKCI, MECOM or MDS1/EVI1) and potentially novel
oncogenes (MYNN). C. A volcano plot presenting the results of expression analyses between amplified and unamplified samples in this region. The
genes in the top right corner are significantly overexpressed in samples with copy number gain (p,0.05; above the red line at –logP 4.32) compared
to samples without copy number change (selected genes are labelled). For full list of differentially expressed genes see Table S5. D. Plot comparing
copy number and expression in all samples for the gene MYNN that showed the highest correlation (r=0.74, Pearson’s test) between copy number
and expression for this region on 3q26.2.
doi:10.1371/journal.pone.0009983.g003
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probeset. Columns 6–11 are derived from differential expression
analyses performed using the ‘‘limma’’ package in R.
Found at: doi:10.1371/journal.pone.0009983.s005 (0.06 MB
PDF)
Table S6 Correlation for all genes highly amplified (CN.5) in
at least 5 samples. This table displays Pearson’s correlation
between copy number and gene expression for all 181 probesets in
regions of high CN gain across the genome. The p-value displayed
is a raw p-value obtained while testing for correlation. * Genes
highly amplified in 4 samples but that were within 10 kb of a copy
number breakpoint of 5 amplified samples.
Found at: doi:10.1371/journal.pone.0009983.s006 (0.03 MB
PDF)
Figure S1 Subtype breakdown of genome wide CN changes. (A)
Overall copy number landscape for the cohort of ovarian cancer
samples. This is similar to Figure 1 with the exception that the y-
axis ranges from 0–100% of samples as opposed to 0–50%. Below
are the distribution of copy number changes for (B) 37 serous
ovarian cancers, (C) 14 endometrioid ovarian cancers, (D) 7
mucinous ovarian cancers and (E) 9 clear cell ovarian cancers. A,
B and C jointly show that the major contributors for the high
frequency changes are serous and endometrioid tumours. Data for
the single tumor classified as undifferentiated is not shown here.
Found at: doi:10.1371/journal.pone.0009983.s007 (0.43 MB TIF)
Figure S2 ‘Cytoband collapsing’ and the exclusion of CNPs. (A)
Shows the steps taken towards obtaining the copy number regions.
The starting data (far left) contains genomic position and copy
number information for segmental overlaps. All segments at this
step of analysis occur with .40% frequency and have 3 or more
copies. Letters a, b, r, s, t, u, v and w refer to genomic start/stop
sites in basepairs. Regions are sorted by chromosome, then by
genomic start and finally by genomic stop positions. Following this
they are annotated with their cytobands and the newly defined
‘‘collapsed’’ region is bounded by the lowest start (a) and highest
stop (b) positions and annotated with the cytoband of origin. The
‘a’ and ‘b’ from here carry through to part B of the figure. Regions
that span two cytobands are listed as a separate group as shown in
Table S4. (B) Shows the rules used to eliminate CNPs from the
cytoband regions. Regions such as ‘‘Amp 4’’ are split into two,
resulting in more regions after CNP elimination than before. (C)
Regions of CNP across the genome and their position in relation
to regions of copy number gain relevant to our study. (i) Global
changes in normal (n=57, green = gain and red = loss) and
tumour (n=72, yellow = gain and blue = loss) samples. We
define a CNP as a change that occurs in at least 5% of normal
samples. CNPs often show both genomic gain and loss at the same
locus in normal samples. (ii) All changes on Chromosome 3 and in
particular a CNP on 3q26.1 between 168.66 and 168.69 Mbp
highlighted by the black oval, observed in .15% of all normal
samples. (iii) The 3q26.1 CNP occurs in the middle of a region of
copy number gain that we investigate further. This CNP region
was removed from the data in accordance with S2-B.
Found at: doi:10.1371/journal.pone.0009983.s008 (0.55 MB
PDF)
Figure S3 Expression of all genes in regions of frequent copy
number gain. This figure displays all genes in 90 regions of copy
number change in terms of their average expression and t-statistic,
resulting from the test for differential expression for each of these
regions between amplified and unamplified samples. Genes
showing a significant differential expression are represented by
red dots and non-significant genes are represented by purple dots.
Only one gene hCG_16001 showed a significant reduction in
expression under the influence of copy number gain. This is a
ribosomal protein L23a pseudogene 42 (RPL23A42) where
RPL23A encodes a ribosomal protein that is a component of the
60S subunit and may be one of the target molecules involved in
mediating growth inhibition by interferon.
Found at: doi:10.1371/journal.pone.0009983.s009 (0.09 MB TIF)
Figure S4 Expression of MYC across various sample groups.
RMA normalised expression of MYC based on Gene 1.0 ST array
data. No significant differences were found between groups of
samples that showed copy number gain in the region and those
that did not.
Found at: doi:10.1371/journal.pone.0009983.s010 (0.15 MB TIF)
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